Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.

scientific article published on 9 April 2009

Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/LEU.2009.68
P698PubMed publication ID19357705
P5875ResearchGate publication ID24267813

P50authorArmin ZebischQ62554773
Gerald HoeflerQ41609985
Heinz SillQ42374295
P2093author name stringJ Troppmair
M Haller
T Goebel
K Hiden
P2860cites workAcute myeloid leukemia in an adult Noonan syndrome patient with PTPN11 mutation.Q46521681
Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutationQ46632829
Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients.Q51926460
Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability.Q54539796
Are mouthwashes a reliable source of constitutional DNA in patients with leukemia?Q57636781
Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1Q73182784
Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activationQ24548297
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathyQ27865193
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIPQ28144497
Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11 gene mutation positive)Q28238801
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemiaQ28305210
Noonan syndrome and related disorders: genetics and pathogenesisQ34560418
Germline gain-of-function mutations in RAF1 cause Noonan syndromeQ34644154
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.Q35080478
Mechanisms of therapy-related carcinogenesisQ36315585
Signaling through RAS-RAF-MEK-ERK: from basics to bedside.Q36754537
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibilityQ36787577
Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemiaQ36835902
Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cellsQ36996036
Genetics of therapy-related myelodysplasia and acute myeloid leukemiaQ37058777
Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancerQ39970092
Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasisQ40358926
RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosisQ40591753
The risk of developing second cancers among survivors of childhood soft tissue sarcomaQ43523794
Therapy-induced malignant neoplasms in Nf1 mutant mice.Q46001683
Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cellsQ46395700
P433issue6
P921main subjectleukemiaQ29496
P304page(s)1049-1053
P577publication date2009-04-09
P1433published inLeukemiaQ6534498
P1476titleLoss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations
P478volume23